TA
ENZ

TLS Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

TLS Advisors’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,616
Closed -$10K – 18
2024
Q4 		$10K Hold
13,616
– – 0.02% 16
2024
Q3 		$15K Hold
13,616
– – 0.03% 17
2024
Q2 		$14K Buy
+13,616
New +$15.3K 0.04% 18

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TLS Advisors's ENZ Position: Q1 2025 in Review

TLS Advisors sold out of Enzo Biochem, Inc. (ENZ) in Q1 2025, closing a stake of 13,616 shares — an estimated $10K sold.

TLS Advisors first reported a position in ENZ in Q2 2024 and held it in 3 quarters. The position peaked at $15K in Q3 2024. 41 funds tracked by Wall St. Rank hold ENZ as of Q1 2025.

  • TLS Advisors reported no remaining Enzo Biochem, Inc. position as of Q1 2025 after selling out during the quarter.
  • TLS Advisors sold 13,616 Enzo Biochem, Inc. shares in Q1 2025, an estimated $10K.
  • TLS Advisors first reported a position in Enzo Biochem, Inc. in Q2 2024 and held it in 3 quarters.
  • TLS Advisors's Enzo Biochem, Inc. position peaked at $15K in Q3 2024.
  • 41 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2025.

Based on TLS Advisors's 13F filing for Q1 2025, filed 12 May 2025.